Whole-genome analysis of the methylome and hydroxymethylome in normal and malignant lung and liver

DNA methylation at the 5-position of cytosine (5mC) is an epigenetic modification that regulates gene expression and cellular plasticity in development and disease. The ten-eleven translocation (TET) gene family oxidizes 5mC to 5-hydroxymethylcytosine (5hmC), providing an active mechanism for DNA demethylation, and it may also provide its own regulatory function. Here we applied oxidative bisulfite sequencing to generate whole-genome DNA methylation and hydroxymethylation maps at single-base resolution in human normal liver and lung as well as paired tumor tissues. We found that 5hmC is significantly enriched in CpG island (CGI) shores while depleted in CGIs themselves, especially in active genes, which exhibit a bimodal distribution of 5hmC around CGI that corresponds to H3K4me1 modifications. Hydroxymethylation on promoters, gene bodies, and transcription termination regions (TTRs) showed strong positive correlation with gene expression within and across tissues, suggesting that 5hmC is a marker of active genes and could play a role in gene expression mediated by DNA demethylation. Comparative analysis of methylomes and hydroxymethylomes revealed that 5hmC is significantly enriched in both tissue-specific DMRs (t-DMRs) and cancer-specific DMRs (c-DMRs), and 5hmC is negatively correlated with methylation changes, especially in non-CGI-associated DMRs. These findings revealed novel reciprocity between epigenetic markers at CGI shores corresponding to differential gene expression in normal tissues and matching tumors. Overall, our study provided a comprehensive analysis of the interplay between the methylome, hydroxymethylome, and histone modifications during tumorigenesis.

[1]  Zachary D. Smith,et al.  DNA methylation: roles in mammalian development , 2013, Nature Reviews Genetics.

[2]  P. Jin,et al.  Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine , 2011, Nature Biotechnology.

[3]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[4]  Rochelle L. Tiedemann,et al.  Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells , 2014, Genome Biology.

[5]  S. Balasubramanian,et al.  Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution , 2012, Science.

[6]  Andrew D. Smith,et al.  Bioinformatics Applications Note Gene Expression Identifying Dispersed Epigenomic Domains from Chip-seq Data , 2022 .

[7]  Lee E. Edsall,et al.  Distinct epigenomic landscapes of pluripotent and lineage-committed human cells. , 2010, Cell stem cell.

[8]  T. Shibata,et al.  Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. , 2011, The American journal of pathology.

[9]  Jian Chen,et al.  Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer , 2014, Science Translational Medicine.

[10]  Colm E. Nestor,et al.  Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. , 2012, Genome research.

[11]  Brent S. Pedersen,et al.  Comb-p: software for combining, analyzing, grouping and correcting spatially correlated P-values , 2012, Bioinform..

[12]  J. Thomson,et al.  Edinburgh Research Explorer 5-hydroxymethylcytosine profiling as an indicator of cellular state , 2013 .

[13]  Monika S. Kowalczyk,et al.  Intragenic enhancers act as alternative promoters. , 2012, Molecular cell.

[14]  S. Su,et al.  IDH mutations in glioma and acute myeloid leukemia. , 2010, Trends in molecular medicine.

[15]  A. Feinberg,et al.  Large-scale hypomethylated blocks associated with Epstein-Barr virus–induced B-cell immortalization , 2014, Genome research.

[16]  G. Schackert,et al.  5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. , 2011, Cancer research.

[17]  Shankar Balasubramanian,et al.  Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine , 2013, Nature Protocols.

[18]  G. Pfeifer,et al.  Genomic mapping of 5-hydroxymethylcytosine in the human brain , 2011, Nucleic acids research.

[19]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[20]  M. Hottiger,et al.  Crosstalk between SET7/9-dependent methylation and ARTD1-mediated ADP-ribosylation of histone H1.4 , 2013, Epigenetics & Chromatin.

[21]  Hao Wu,et al.  Reversing DNA Methylation: Mechanisms, Genomics, and Biological Functions , 2014, Cell.

[22]  N. Heintz,et al.  MeCP2 binds to 5hmc enriched within active genes and accessible chromatin in the nervous system , 2012, Cell.

[23]  Chuan He,et al.  5-Formyl- and 5-carboxyl-cytosine reduce the rate and substrate specificity of RNA polymerase II transcription , 2012, Nature Structural &Molecular Biology.

[24]  G. Hon,et al.  Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome , 2012, Cell.

[25]  Rong Li,et al.  Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain , 2013, Genome Biology.

[26]  William A. Pastor,et al.  TETonic shift: biological roles of TET proteins in DNA demethylation and transcription , 2013, Nature Reviews Molecular Cell Biology.

[27]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[28]  Z. Ling,et al.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.

[29]  Lee E. Edsall,et al.  5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. , 2014, Molecular cell.

[30]  Jun Hu,et al.  OSA: a fast and accurate alignment tool for RNA-Seq , 2012, Bioinform..

[31]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[32]  S. Vowler,et al.  5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer , 2015, Genome Biology.

[33]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[34]  Abraham J. Khorasani,et al.  Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma , 2012, Cell.

[35]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[36]  Swati Kadam,et al.  5-hydroxymethylcytosine and its potential roles in development and cancer , 2013, Epigenetics & Chromatin.

[37]  A. Feinberg,et al.  Increased methylation variation in epigenetic domains across cancer types , 2011, Nature Genetics.

[38]  H. Aburatani,et al.  Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation , 2012, Cancer science.

[39]  B. Langmead,et al.  BSmooth: from whole genome bisulfite sequencing reads to differentially methylated regions , 2012, Genome Biology.

[40]  H. Cedar,et al.  Linking DNA methylation and histone modification: patterns and paradigms , 2009, Nature Reviews Genetics.

[41]  Michael Q. Zhang,et al.  Integrative analysis of 111 reference human epigenomes , 2015, Nature.

[42]  Andrew P. Feinberg,et al.  Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host , 2013, Nature Reviews Cancer.

[43]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.